Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference 18 February 2025
13 slides from Immuron's conference presentation, Feb 19, 2025
Slide 1: Emerging Growth Conference 18 February 2025
EMERGING GROWTH CONFERENCE 18 FEBRUARY 2025 S teven Lydeamore - CEO NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended
Slide 3: Revenue Generating with Strong Pipeline
REVENUE GENERATING WITH STRONG PIPELINE 3 Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases 18 February 2025 30 October 2024 December 2024 Quarterly rev
Slide 4: Continued Strong Sales Growth
CONTINUED STRONG SALES GROWTH o Global sales increased by 172% in the 2024 fiscal year to a record A$4.9 million compared to A$1.8 million in FY23 o Half Yearly sales record in Dec 24 A$4.0 million, up 70% pcp o Australia o FY24: a record A$3.75 million; up 223% o Half Yearly sales in December 2024
Slide 5: Expansion of Travelan Distribution
EXPANSION OF TRAVELAN® DISTRIBUTION 5
Slide 6: Consumer Marketing Activity Driving Travelan Sales Growth
CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, consideration and engagement o Ranging across major retailers (Australia, Canada) o In - store positioning and promotion o Retailer catalogues o Search and social media marketing o Social competitions o User g
Slide 7: Strong Pipeline with Near Term Milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES 7 7 7
Slide 8: World First Triple Mechanism of Action for CDI IMM-529
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM - 529: pre - IND filed with FDA July 2024; successful pre - IND meeting IMM - 529 will be indicated for the treatment of recurrent C. difficile infection Indication / Target Population • Novel antibody - containing therapeutic which neutralizes C. d
Slide 9: Immuron's Clinical Programs – Opportunity Assessment
9 IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80%
Slide 10: New Project: IMM-986 Targeting VRE
NEW PROJECT: IMM - 986 TARGETING VRE 10 In collaboration with Monash University, Immuron is developing IMM - 986 to specifically target Vancomycin - resistant enterococci (VRE) . The objective of this collaboration is to determine whether VRE - specific colostrum results in decolonisation or removal
Slide 11: Travelan Progresses Towards Phase 3
TRAVELAN® PROGRESSES TOWARDS PHASE 3 11 Travelan® (IMM - 124E) Phase 2 o Travelan® IND Approval – December 2022 o Study Initiation – May 2023 o First cohort recruitment completed – July 2023 o Presentations at Military Health System Research Symposium – August 2023 o Second cohort recruitment comple
Slide 12: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 12 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 13: Scientific references
Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sympo
Immuron — Emerging Growth Conference 18 February 2025 on 6ix